Fitzgerald Joan C, Duffy Niamh, Cattaruzzi Giacomo, Vitrani Francesco, Paulitti Alice, Mazzarol Flavia, Mauro Prisca, Sfiligoj Antonio, Curcio Francesco, Jones Deirdre M, McInerney Veronica, Krawczyk Janusz, Kelly Jack, Finnerty Andrew, McDonagh Katya, McCabe Una, Duggan Matthew, Connolly Lauren, Shaw Georgina, Murphy Mary, Barry Frank
Regenerative Medicine Institute (REMEDI), National University of Ireland Galway, Galway, Ireland.
VivaBioCell S.p.A., Udine, Italy.
Front Bioeng Biotechnol. 2022 Mar 9;10:834267. doi: 10.3389/fbioe.2022.834267. eCollection 2022.
In recent years mesenchymal stromal cells (MSCs) have received a great deal of interest for the treatment of major diseases, but clinical translation and market authorization have been slow. This has been due in part to a lack of standardization in cell manufacturing protocols, as well as a lack of biologically meaningful cell characterization tools and release assays. Cell production strategies to date have involved complex manual processing in an open environment which is costly, inefficient and poses risks of contamination. The NANT 001 bioreactor has been developed for the automated production of small to medium cell batches for autologous use. This is a closed, benchtop system which automatically performs several processes including cell seeding, media change, real-time monitoring of temperature, pH, cell confluence and cell detachment. Here we describe a validation of the bioreactor in an environment compliant with current good manufacturing practice (cGMP) to confirm its utility in replacing standardized manual processing. Stromal vascular fraction (SVF) was isolated from lipoaspirate material obtained from healthy donors. SVF cells were seeded in the bioreactor. Cell processing was performed automatically and cell harvesting was triggered by computerized analysis of images captured by a travelling microscope positioned beneath the cell culture flask. For comparison, the same protocol was performed in parallel using manual methods. Critical quality attributes (CQA) assessed for cells from each process included cell yield, viability, surface immunophenotype, differentiation propensity, microbial sterility and endotoxin contamination. Cell yields from the bioreactor cultures were comparable in the manual and automated cultures and viability was >90% for both. Expression of surface markers were consistent with standards for adipose-derived stromal cell (ASC) phenotype. ASCs expanded in both automated and manual processes were capable of adipogenic and osteogenic differentiation. Supernatants from all cultures tested negative for microbial and endotoxin contamination. Analysis of labor commitment indicated considerable economic advantage in the automated system in terms of operator, quality control, product release and management personnel. These data demonstrate that the NANT 001 bioreactor represents an effective option for small to medium scale, automated, closed expansion of ASCs from SVF and produces cell products with CQA equivalent to manual processes.
近年来,间充质基质细胞(MSCs)在重大疾病治疗方面备受关注,但临床转化和市场授权进展缓慢。部分原因在于细胞制造方案缺乏标准化,以及缺乏具有生物学意义的细胞表征工具和放行检测方法。迄今为止,细胞生产策略涉及在开放环境中进行复杂的手工处理,成本高、效率低且存在污染风险。NANT 001生物反应器已被开发用于自动生产小至中等规模的细胞批次以供自体使用。这是一个封闭的台式系统,可自动执行多个过程,包括细胞接种、培养基更换、实时监测温度、pH值、细胞汇合度和细胞脱离。在此,我们描述了该生物反应器在符合现行良好生产规范(cGMP)的环境中的验证,以确认其在替代标准化手工处理方面的效用。从健康供体获取的脂肪抽吸物中分离出基质血管成分(SVF)。将SVF细胞接种到生物反应器中。细胞处理自动进行,细胞收获由位于细胞培养瓶下方的移动显微镜捕获的图像的计算机分析触发。为作比较,使用手工方法并行执行相同方案。对每个过程的细胞评估的关键质量属性(CQA)包括细胞产量、活力、表面免疫表型、分化倾向、微生物无菌性和内毒素污染。生物反应器培养物的细胞产量在手工培养和自动培养中相当,两者的活力均>90%。表面标志物的表达与脂肪来源基质细胞(ASC)表型标准一致。在自动和手工过程中扩增的ASC均能够进行成脂和成骨分化。所有培养物上清液的微生物和内毒素污染检测均为阴性。劳动投入分析表明,在操作员、质量控制、产品放行和管理人员方面,自动系统具有显著的经济优势。这些数据表明,NANT 001生物反应器是从小至中等规模自动封闭扩增来自SVF的ASC的有效选择,并能生产出CQA与手工过程相当的细胞产品。